324 related articles for article (PubMed ID: 31919755)
1. Kratom (Mitragyna Speciosa) Liver Injury: A Comprehensive Review.
Schimmel J; Dart RC
Drugs; 2020 Feb; 80(3):263-283. PubMed ID: 31919755
[TBL] [Abstract][Full Text] [Related]
2. Patterns and reasons for kratom (Mitragyna speciosa) use among current and former opioid poly-drug users.
Singh D; Yeou Chear NJ; Narayanan S; Leon F; Sharma A; McCurdy CR; Avery BA; Balasingam V
J Ethnopharmacol; 2020 Mar; 249():112462. PubMed ID: 31816368
[TBL] [Abstract][Full Text] [Related]
3. Chemical composition and biological effects of kratom (Mitragyna speciosa): In vitro studies with implications for efficacy and drug interactions.
Todd DA; Kellogg JJ; Wallace ED; Khin M; Flores-Bocanegra L; Tanna RS; McIntosh S; Raja HA; Graf TN; Hemby SE; Paine MF; Oberlies NH; Cech NB
Sci Rep; 2020 Nov; 10(1):19158. PubMed ID: 33154449
[TBL] [Abstract][Full Text] [Related]
4. Accelerated Solvent Extractions (ASE) of
Goh YS; Karunakaran T; Murugaiyah V; Santhanam R; Abu Bakar MH; Ramanathan S
Molecules; 2021 Jun; 26(12):. PubMed ID: 34204457
[No Abstract] [Full Text] [Related]
5. Drug-Induced Liver Injury Caused by Kratom Use as an Alternative Pain Treatment Amid an Ongoing Opioid Epidemic.
Osborne CS; Overstreet AN; Rockey DC; Schreiner AD
J Investig Med High Impact Case Rep; 2019; 7():2324709619826167. PubMed ID: 30791718
[TBL] [Abstract][Full Text] [Related]
6. Update on the Pharmacology and Legal Status of Kratom.
Prozialeck WC
J Am Osteopath Assoc; 2016 Dec; 116(12):802-809. PubMed ID: 27893147
[TBL] [Abstract][Full Text] [Related]
7. A validated method for the quantification of mitragynine in sixteen commercially available Kratom (Mitragyna speciosa) products.
Fowble KL; Musah RA
Forensic Sci Int; 2019 Jun; 299():195-202. PubMed ID: 31059866
[TBL] [Abstract][Full Text] [Related]
8. Suspected Adulteration of Commercial Kratom Products with 7-Hydroxymitragynine.
Lydecker AG; Sharma A; McCurdy CR; Avery BA; Babu KM; Boyer EW
J Med Toxicol; 2016 Dec; 12(4):341-349. PubMed ID: 27752985
[TBL] [Abstract][Full Text] [Related]
9. Comparative Pharmacokinetics of Mitragynine after Oral Administration of Mitragyna speciosa (Kratom) Leaf Extracts in Rats.
Avery BA; Boddu SP; Sharma A; Furr EB; Leon F; Cutler SJ; McCurdy CR
Planta Med; 2019 Mar; 85(4):340-346. PubMed ID: 30452072
[TBL] [Abstract][Full Text] [Related]
10. Evaluating the hematological and clinical-chemistry parameters of kratom (Mitragyna speciosa) users in Malaysia.
Singh D; Müller CP; Murugaiyah V; Hamid SBS; Vicknasingam BK; Avery B; Chear NJY; Mansor SM
J Ethnopharmacol; 2018 Mar; 214():197-206. PubMed ID: 29248450
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive methodology for identification of Kratom in police laboratories.
Kowalczuk AP; Łozak A; Zjawiony JK
Forensic Sci Int; 2013 Dec; 233(1-3):238-43. PubMed ID: 24314525
[TBL] [Abstract][Full Text] [Related]
12. Intrahepatic cholestasis following abuse of powdered kratom (Mitragyna speciosa).
Kapp FG; Maurer HH; Auwärter V; Winkelmann M; Hermanns-Clausen M
J Med Toxicol; 2011 Sep; 7(3):227-31. PubMed ID: 21528385
[TBL] [Abstract][Full Text] [Related]
13. Liver injury associated with kratom, a popular opioid-like product: Experience from the U.S. drug induced liver injury network and a review of the literature.
Ahmad J; Odin JA; Hayashi PH; Fontana RJ; Conjeevaram H; Avula B; Khan IA; Barnhart H; Vuppalanchi R; Navarro VJ;
Drug Alcohol Depend; 2021 Jan; 218():108426. PubMed ID: 33257199
[TBL] [Abstract][Full Text] [Related]
14. Kratom policy: The challenge of balancing therapeutic potential with public safety.
Prozialeck WC; Avery BA; Boyer EW; Grundmann O; Henningfield JE; Kruegel AC; McMahon LR; McCurdy CR; Swogger MT; Veltri CA; Singh D
Int J Drug Policy; 2019 Aug; 70():70-77. PubMed ID: 31103778
[TBL] [Abstract][Full Text] [Related]
15. Kratom (Mitragyna speciosa) Validation: Quantitative Analysis of Indole and Oxindole Alkaloids Reveals Chemotypes of Plants and Products.
Manwill PK; Flores-Bocanegra L; Khin M; Raja HA; Cech NB; Oberlies NH; Todd DA
Planta Med; 2022 Aug; 88(9-10):838-857. PubMed ID: 35468648
[TBL] [Abstract][Full Text] [Related]
16. Rapid detection by direct analysis in real time-mass spectrometry (DART-MS) of psychoactive plant drugs of abuse: the case of Mitragyna speciosa aka "Kratom".
Lesiak AD; Cody RB; Dane AJ; Musah RA
Forensic Sci Int; 2014 Sep; 242():210-218. PubMed ID: 25086346
[TBL] [Abstract][Full Text] [Related]
17. Synthetic and Receptor Signaling Explorations of the Mitragyna Alkaloids: Mitragynine as an Atypical Molecular Framework for Opioid Receptor Modulators.
Kruegel AC; Gassaway MM; Kapoor A; Váradi A; Majumdar S; Filizola M; Javitch JA; Sames D
J Am Chem Soc; 2016 Jun; 138(21):6754-64. PubMed ID: 27192616
[TBL] [Abstract][Full Text] [Related]
18. Is kratom (
Leong Abdullah MFI; Tan KL; Narayanan S; Yuvashnee N; Chear NJY; Singh D; Grundmann O; Henningfield JE
Clin Toxicol (Phila); 2021 May; 59(5):400-408. PubMed ID: 32870119
[TBL] [Abstract][Full Text] [Related]
19. Pharmacologic and clinical assessment of kratom.
White CM
Am J Health Syst Pharm; 2018 Mar; 75(5):261-267. PubMed ID: 29255059
[TBL] [Abstract][Full Text] [Related]
20. Metabolite profiling and identification of enzymes responsible for the metabolism of mitragynine, the major alkaloid of
Kamble SH; Sharma A; King TI; León F; McCurdy CR; Avery BA
Xenobiotica; 2019 Nov; 49(11):1279-1288. PubMed ID: 30547698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
